SCHEMBL62795

SCHEMBL62795

CCOC(=O)c1ccc(N2CCNCC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.56
HTT P42858 2/20 0.56
ALDH1A1 P00352 4/20 0.55
TSHR P16473 2/20 0.55
USP2 O75604 1/20 0.55
HSD17B10 Q99714 1/20 0.55
HSP90AA1 P07900 1/20 0.54
CACNA1B Q00975 1/20 0.54
APBA1 Q02410 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
ADRB1 P08588 2/20 0.53
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
ESR1 P03372 1/20 0.51
CA7 P43166 1/20 0.51
CA9 Q16790 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7313025 0.98 HPGD (0.55) HPGDHTTALDH1A1TSHRUSP2
Hydrochloric Acid SCHEMBL9742136 0.98 HPGD (0.55) HPGDHTTALDH1A1TSHRUSP2
Bromide SCHEMBL15106751 0.98 HPGD (0.55) HPGDHTTALDH1A1TSHRUSP2
SCHEMBL64895 0.94 HPGD (0.51) HPGDHTTALDH1A1TSHRUSP2
SCHEMBL20188098 0.89 HPGD (0.65) HPGDHTTALDH1A1TSHRHSP90AA1
SCHEMBL22015905 0.89 HPGD (0.65) HPGDHTTALDH1A1TSHRHSP90AA1
Tert-Butyl Formate SCHEMBL27911780 0.89 HPGD (0.46) HPGDHTTALDH1A1TSHRUSP2
SCHEMBL3918577 0.86 TSHR (0.56) HPGDALDH1A1TSHRUSP2HSD17B10
SCHEMBL3898465 0.86 HPGD (0.61) HPGDHTTALDH1A1TSHRHSD17B10
SCHEMBL28242074 0.86 HPGD (0.61) HPGDHTTALDH1A1TSHRHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 509 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102131792-B Process for preparation of apoptosis promoter ABT-263 ABBOTT LAB 2014-05-07 CN claimed
EP-2307393-B1 A PROCESS FOR THE PREPARATION OF THE APOPTOSIS PROMOTER ABT-263 ABBOTT LAB (US) 2013-04-10 EP claimed
US-8168784-B2 Processes to make apoptosis promoters ABBOTT LABORATORIES (US) 2012-05-01 US claimed
US-8084607-B2 Apoptosis promoters ABBOTT LABORATORIES (US) 2011-12-27 US claimed
JP-2011525182-A 2011-09-15 JP claimed
CN-102131792-A Process for preparation of apoptosis promoter abt-263 ABBOTT LAB 2011-07-20 CN claimed
EP-2307393-A1 A PROCESS FOR THE PREPARATION OF THE APOPTOSIS PROMOTER ABT-263 Abbott Laboratories (US) 2011-04-13 EP claimed
US-20100022773-A1 APOPTOSIS PROMOTERS ABBVIE INC. 2010-01-28 US claimed
US-20090318689-A1 Processes To Make Apoptosis Promoters ABBOTT LABORATORIES (US) 2009-12-24 US claimed
WO-2009155386-A1 A PROCESS FOR THE PREPARATION OF THE APOPTOSIS PROMOTER ABT-263 ABBOTT LABORATORIES (US) 2009-12-23 WO claimed
EP-4743446-A1 NITRO-CONTAINING COMPOUNDS THAT KILL MYCOBACTERIA Board of Trustees of Michigan State University (US) 2026-05-20 EP disclosed
US-20260092057-A1 BCL-XL/BCL-2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-02 US disclosed
US-20260014147-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2026-01-15 US disclosed
US-20260001893-A1 SMALL MOLECULE MODULATORS OF STAT6 GILEAD SCIENCES INC (US) 2026-01-01 US disclosed
EP-4667469-A1 COMPOUND CONTAINING TRIFLUOROMETHYLSULFONYL Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2025-12-24 EP disclosed
US-4882330-A 1-aryloxy-4-[((4-aryl)-1-piperazinyl]-2-butanols useful as antiallergy agents A. H. ROBINS COMPANY, INCORPORATED (US) 1989-11-21 US disclosed
EP-0269383-A2 1-Aryloxy-4-[(4-aryl)-1-piperazinyl]-2-butanols useful as antiallergy agents A.H. ROBINS COMPANY, INCORPORATED (US) 1988-06-01 EP disclosed
US-4616086-A ANTICOAGULANTS BOEHRINGER MANNHEIM GMBH (DE) 1986-10-07 US disclosed
EP-0156433-A2 Anti-virally active pyridazinamines JANSSEN PHARMACEUTICA N.V. (BE) 1985-10-02 EP disclosed
US-4446133-A ANTIARTHRITIC AGENTS Misuitoatsu Chemicals, Inc. (JP) 1984-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318689-A1 Processes To Make Apoptosis Promoters BAX, BCL2, CCAR2 HPGD 2451/4885HTT 3001/4885ALDH1A1 3738/4885
US-20100022773-A1 APOPTOSIS PROMOTERS BAX, BCL2, API5 HPGD 1399/4885HTT 3472/4885ALDH1A1 3731/4885
US-20260092057-A1 BCL-XL/BCL-2 DEGRADERS AND USES THEREOF BCL2L2, BCL2A1, BCL2L1 HPGD 1899/4885HTT 2916/4885ALDH1A1 1304/4885
US-20260001893-A1 SMALL MOLECULE MODULATORS OF STAT6 STAT6, NCOR1, NCOR2 HPGD 3666/4885HTT 3252/4885ALDH1A1 3636/4885
US-20260014147-A1 STAT6 DEGRADERS STAT6, NCOR1, CBR1 HPGD 1725/4885HTT 1870/4885ALDH1A1 1790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.